This issue has been addressed in several preclinical and clinical studies, which indicate that EGFR blockade and BRAF targeting act synergistically to inhibit ERK pathway signaling in BRAFV600E mutant colon cancers [3, 16, 19]. Here, EGFR is linked to colonic neoplasm.